Management of Chronic Respiratory Conditions

Guideline Recommendations

The American College of Chest Physicians found no consistent favorable effect of mucokinetic agents on cough in acute bronchitis, with conflicting trial results, and therefore does not recommend their use 1
Antitussive agents, like dextromethorphan, are occasionally useful and can be offered for short-term symptomatic relief only, with a recommendation Grade C (fair quality evidence, small/weak benefit) 1
The British Thoracic Society guidelines suggest considering a 6-month trial of carbocysteine, a different mucoactive agent, only if difficulty with sputum expectoration persists, with continuation only if ongoing clinical benefit is demonstrated 2
First-line therapy for chronic bronchitis should be short-acting bronchodilators (β-agonists or ipratropium bromide), not expectorants 3

If chronic bronchitis/COPD is confirmed, optimize disease-specific therapy with short-acting bronchodilators as first-line, inhaled corticosteroids for patients with FEV1 <50% predicted or frequent exacerbations, and consider long-acting β-agonist plus inhaled corticosteroid combination for persistent symptoms 3, 4
Consider alternative mucoactive therapy, such as a 6-month trial of carbocysteine, only after optimization of standard treatments, and continue only if demonstrable clinical benefit 2
For severe, refractory cases, long-term macrolide antibiotics (azithromycin) may be considered by a respiratory specialist, but requires extensive monitoring including ECG, liver function tests, and sputum cultures 5, 6